ARCHIVES

Gleevec Approval Sets Record For FDA Review: 73 Days

This article is from The Cancer Letter archive.

Vol. 24 No. 5 | May 25, 2001

Download PDF Visit The Full Archive

Related Articles

Studies Test New Agents Offering Relief From Treatment-Related Side Effects

July 30, 2004

Be More Aggressive On National Issues, ASCO Urged

May 20, 1977

ODAC Reviews Post-Marketing Studies for Eight Indications

February 21, 2003

Pooled Analysis of Two LUX-Lung Trials Shows Prolonged Survival with Afatinib

June 27, 2014

Georgetown Sponsors Oncology Agent Development Meeting

February 21, 2003

In Congress: Varmus Defends Raise In Cancer Funding; Porter Says Allocation Difficult If No Agreement On Tobacco Legislation

March 13, 1998